MyelofibrosisMETERNCT05444972
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
An observational study of Myelofibrosis, run by AbbVie at 66 sites in 14 countries.
Trial summary
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myelofibrosis
- How many people
- 998 participants
- Where
- 66 sitesin 14 countries
- Study dates
- 23 Aug 2022to 14 Nov 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult participants patients diagnosed with myelofibrosis and treated on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Who may be able to join
- Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
- Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Who cannot join
- Having received MF treatment in a clinical trial setting.
Trial locations and contacts
66 sites in 14 countries.
66 sites in 14 countries
Italy10 sites
IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 245716
Bologna, 40138
ASST Spedali civili di Brescia /ID# 244910
Brescia, 25123
Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 245149
Cona, Ferrara, 44124
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 244909
Milan, 20122
Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 245566
Novara, 28100
Azienda Ospedaliera Universitaria Paolo Giaccone /ID# 245075
Palermo, 90127
Azienda Ospedaliera di Perugia /ID# 245415
Perugia, Umbria, 06129
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 245335
Rome, Lazio, 00168
ASST Sette Laghi /ID# 245443
Varese, 21100
Ospedale Belcolle /ID# 245726
Viterbo, 01100
Greece8 sites
General University Hospital of Alexandroupolis /ID# 246161
Alexandroupoli, 68100
General Hospital of Athens Laiko /ID# 246159
Athens, Attica, 11527
University General Hospital Attikon /ID# 246167
Athens, Attica, 12462
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 246165
Athens, 10676
University General Hospital of Heraklion PA.G.N.I /ID# 246163
Heraklion, Crete, 71500
University General Hospital of Ioannina /ID# 246160
Ioannina, 45500
METAXA Cancer Hospital of Piraeus /ID# 246164
Piraeus, 18737
University General Hospital of Patras /ID# 246162
RION Patras Achaia, 26504
Canada7 sites
Nova Scotia Health /ID# 248393
Halifax, Nova Scotia, B3H 1V7
Juravinski Cancer Centre /ID# 251334
Hamilton, Ontario, L8V 1C3
CSSS Alphonse-Desjardins, CHAU de Levis /ID# 250449
Lévis, Quebec, G6V 3Z1
CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 250563
Montreal, Quebec, H1T 2M4
Jewish General Hospital /ID# 250674
Montreal, Quebec, H3T 1E2
Princess Margaret Cancer Centre /ID# 249748
Toronto, Ontario, M5G 2M9
St. Paul's Hospital /ID# 249719
Vancouver, British Columbia, V6Z 1Y6
Turkey (Türkiye)7 sites
Gulhane Askeri Tip Academy /ID# 244134
Ankara, 06010
Hacettepe University Medical Faculty /ID# 244131
Ankara, 06230
Dicle Universitesi Tip /ID# 244137
Diyarbakır, 21200
Trakya University Medical Facu /ID# 244132
Edirne, Istanbul, 22030
Bagcilar Medipol Mega Universite Hastanesi /ID# 244133
Istanbul, 34214
Ege University Medical Faculty /ID# 244130
Izmir, 35040
Inonu University Medical Faculty /ID# 244135
Malatya, 44280
Colombia5 sites
Organizacion Clinica Bonnadona -PREVENIR S.A.S. /ID# 244589
Baranquilla, Atlántico, 080016
Fundacion Santa Fe de Bogota /ID# 244588
Bogota, Cundinamarca, 11011
Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 246108
Bogota DC, Cundinamarca, 111221
Clínica Imbanaco S.A.S /ID# 248465
Cali, 760042
Hospital Pablo Tobon Uribe /ID# 244525
Medellín, 50034
United States4 sites
UAB Comprehensive Cancer Center /ID# 252767
Birmingham, Alabama, 35233-1932
Brigham & Women's Hospital /ID# 254312
Boston, Massachusetts, 02115
Gabrail Cancer Center Research /ID# 252768
Canton, Ohio, 44718
Wellness Oncology & Hematology /ID# 255591
West Hills, California, 91307-1468
Australia4 sites
Royal Adelaide Hospital /ID# 246583
Adelaide, South Australia, 5000
Townsville University Hospital /ID# 246585
Douglas, Queensland, 4814
Fiona Stanley Hospital /ID# 246584
Murdoch, Western Australia, 6150
Royal Perth Hospital /ID# 246586
Perth, Western Australia, 6000
Poland4 sites
Specjalistyczna Praktyka Lekarska Witold Prejzner /ID# 250516
Gdansk, Pomeranian Voivodeship, 80-337
Joanna Góra-Tybor Specjalistyczna Praktyka Lekarska /ID# 250495
Lodz, 90-712
Specjalistyczna Praktyka Lekarska Grzegorz Helbig /ID# 250515
Orzesze, 43-180
Krzysztof Mądry Praktyka Lekarska /ID# 250485
Warsaw, Masovian Voivodeship, 01-309
Romania4 sites
MedLife - Policlinica de Diagnostic Rapid /ID# 244395
Brasov, Brașov County, 500152
Spitalul Clinic Colentina /ID# 245620
Bucharest, 020121
Institutul Clinic Fundeni /ID# 245939
Bucharest, 925200
Institutul Oncologic Prof Dr I Chiricuta /ID# 244393
Cluj-Napoca, 400015
Argentina3 sites
Hospital Italiano de Buenos Aires /ID# 244373
Ciudad Autonoma Buenos Aires, Ciuadad Autonoma de Buenos Aires, 1199
Fundaleu /Id# 244371
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, 1114
Instituto FIDES /ID# 245526
La Plata, Buenos Aires, 1900
Mexico3 sites
Hospital de Especialidades CMN SigloXXI /ID# 244748
Mexico City, Mexico City, 06720
Hospital General de Mexico /ID# 244749
Mexico City, 06720
Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 244750
Monterrey, Nuevo León, 64610
Portugal3 sites
Centro Hospitalar e Universitario de Coimbra, EPE /ID# 244687
Coimbra, 3000-075
Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 248203
Lisbon, 1649-035
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 244400
Porto, 4200-319
Brazil2 sites
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 247394
São Paulo, São Paulo, 05652-900
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 247392
São Paulo, 05403-000
Taiwan2 sites
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 250092
Kaohsiung City, 807
National Taiwan University Hospital /ID# 250093
Taipei, 100
About this study
Official title: A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Read more
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
- Conditions
- Myelofibrosis
- Keywords
- Myelofibrosis, Cancer
- Medical subject headings
- Primary Myelofibrosis, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Participants Undergoing Chart Review | Participants treated for myelofibrosis undergoing chart review. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment
Time from diagnosis of MF to initial treatment.
Measured: Up to Week 156
Duration of Initial Treatment
Duration of initial treatment.
Measured: Up to Week 156
Duration of Second Treatment
Duration of second treatment.
Measured: Up to Week 156
Duration of Subsequent Treatments
Duration of subsequent treatments.
Measured: Up to Week 156
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2022
- Study start23 Aug 2022
- Primary completion14 Nov 2023
- Study completion14 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for MyelofibrosisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 998 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05444972
- Sponsor's protocol ID
- H23-122
- Acronym
- METER
- Status last verified
- Dec 2023
- First submitted
- 23 Jun 2022
- Last updated
- 11 Dec 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Gupta V, Tomuleasa C, Barranco Lampon GI, Hou HA, Helbig G, Vachhani P, Symeonidis A, Haznedaroglu I, Galvez K, Tatsch F, Chopra AS, Zhang M, Vizkelety T, Murray B, Ross DM. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025 Mar 11;9(5):1105-1116. doi: 10.1182/bloodadvances.2024014625.
PubMed 39729499
Study at a glance
From the registry record, last updated by the sponsor on 11 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
- ClinicalTrials.gov ID
- NCT05444972
- Acronym / sponsor ID
- METER / H23-122
- Conditions
- Myelofibrosis
- Keywords
- Myelofibrosis, Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 998 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 23 Aug 2022 (actual)
- Primary completion
- 14 Nov 2023 (actual)
- Study completion
- 14 Nov 2023 (actual)
- First posted
- 6 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Myelofibrosis (MF) is a rare blood cancer, characterized by extensive fibrosis (scarring) of the bone marrow. It is one of a group of cancers known as myeloproliferative neoplasms (MPNs) in which bone marrow cells that produce blood cells develop and function abnormally. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with Myelofibrosis.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants Undergoing Chart Review | – | –Participants treated for myelofibrosis undergoing chart review. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult participants patients diagnosed with myelofibrosis and treated on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Key inclusion criteria (2 listed)
- Treated for myelofibrosis (MF) [primary myelofibrosis (PMF) and secondary myelofibrosis (SMF)].
- Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Key exclusion criteria (1 listed)
- Having received MF treatment in a clinical trial setting.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment
Time frame: Up to Week 156
Time from diagnosis of MF to initial treatment.
Duration of Initial Treatment
Time frame: Up to Week 156
Duration of initial treatment.
Duration of Second Treatment
Time frame: Up to Week 156
Duration of second treatment.
Duration of Subsequent Treatments
Time frame: Up to Week 156
Duration of subsequent treatments.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Dec 2023.
- Derived from this study: PubMed 39729499Gupta V, Tomuleasa C, Barranco Lampon GI, Hou HA, Helbig G, Vachhani P, Symeonidis A, Haznedaroglu I, Galvez K, Tatsch F, Chopra AS, Zhang M, Vizkelety T, Murray B, Ross DM. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025 Mar 11;9(5):1105-1116. doi: 10.1182/bloodadvances.2024014625.
- Individual participant dataSharing planned: Undecided
Related trials for Myelofibrosis
Active, not recruitingPhase 3
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Myelofibrosis
RecruitingPhase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
RecruitingPhase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
Not yet recruitingPhase 1
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
RecruitingPhase 1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
66 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myelofibrosis, run by AbbVie at 66 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 66 sites in Italy, Greece, Canada, Turkey (Türkiye), Colombia and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time from Diagnosis of Myelofibrosis (MF) to Initial Treatment (time frame: Up to Week 156). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05444972, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2023; AzTrials last refreshed its copy on 6 Nov 2026.